课题基金 / 基金详情

Development of a salt-based nanomedicine for non-muscle invasive bladder cancer

Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
开发用于非肌肉浸润性膀胱癌的盐基纳米药物
批准号:
10482565
负责人:
Zhi Liu
金额:
$39.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-05 至 2025-04-30

项目摘要

项目成果

Zhi Liu的其他基金

相似基金

相关文献

中文摘要
翻译
摘要
英文摘要
Abstract Bladder cancer comprises 7% of new cancer diagnoses in the US. It is the sixth most prevalent malignancy, and has the highest lifetime treatment costs among all cancer types due to the need for lifelong surveillance. Early stage bladder cancer, also known as non-muscle-invasive bladder cancer (NMIBC), represents 75% of new bladder cancer cases. The standard treatment is transurethral resection of bladder tumor (TURBT), followed by intravescical therapy with chemotherapeutics such as mitomycin C or Bacille Calmette-Guérin (BCG). However, ~30% patients are refractory to BCG. Chemotherapies are assocaited with relatively high recurrence rates and ineffective as a second-line treatment for patients unresponsive to BCG. Meanwhile, no new intravesical drugs have been approved since 1998. There is an unmet clinical need for new NMIBC therapies. Athna Biotech, Inc. is developing a sodium chloride nanoparticle (SCNP) based cancer therapeutic. SCNPs deliver large amounts of Na+ and Cl- into cancer cells, by doing so disrupts the osmotic balance across the plasma membrane. Uniquely, SCNPs induce immunogenic cell death or ICD. This means that SCNPs essentially produce a vaccine in situ out of dying cancer cells, eliciting an antitumor immunity that prevents tumor recurrence and progression. SCNPs are intravesically instilled into the affected bladder to kill residual cancer cells after TURBT. After the treatment, SCNPs degrade to constitute ions that are excreted in the urine. The procedure is safe and can be applied repeatedly without causing local or systemic toxicity. In Phase I, we will test the efficacy of SCNPs in a mouse orthotopic bladder cancer model. In Phase II, we will evaluate the efficacy of SCNPs in an expanded pre-clinical study and perform IND-enabling pharmacokinetics and toxicity studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a radiation-activatable nanoparticle for lung cancer therapy
  • 批准号:
    10259278
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2021
  • 负责人:
    Zhi Liu
  • 依托单位:
Inflammasome-gasdermin axis in bullous pemphigoid
Inflammasome-gasdermin axis in bullous pemphigoid
Eosinophils in Bullous Pemphigoid
海外基金